Brief: China Regenerative Medicine International Posts H1 Revenue Of HKD59.78 Mln
23/08/2024 15:27
Aug 23 (Reuters) - China Regenerative Medicine International H1 gross profit HKD 39.49 million. * H1 operating expenses HKD 22.11 million * H1 revenue HKD 59.78 million
Recent news on China Regenerative Medicine International
See all newsBrief: China Regenerative Medicine International Expects FY Profit To Increase At Least 28%
Brief: China Regenerative Medicine International Says Yan Shibin Will Be Appointed As CFO
Brief: China Regenerative Medicine International Posts H1 Revenue Of HKD59.78 Mln
Brief: China Regenerative Medicine International Posts FY Loss Attributable HK$107.7 Mln
Brief: China Regenerative Medicine International Says Subscription Of Increased Registered Capital